Asymmetric dimethylarginine levels in children with sickle cell disease and its correlation to tricuspid regurgitant jet velocity

European Journal of Haematology

Volumn 91, Issue 1, 2013, Pages 55-61

  El Shanshory, Mohamed ^a   Badraia, Ibrahim ^a   Donia, Amr ^a   Abd El hameed, Faten ^a   Mabrouk, Mokhtar ^b  

^a TANTA UNIVERSITY   (Egypt)

^b Tanta University   (Egypt)

Author keywords

Asymmetric dimethylarginine; Sickle cell disease; Tricuspid regurgitant jet velocity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FERRITIN; LACTATE DEHYDROGENASE; N(G),N(G) DIMETHYLARGININE;

ARTICLE; BLOOD CELL COUNT; BLOOD LEVEL; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; TRICUSPID REGURGITANT JET VELOCITY;

ADOLESCENT; ANEMIA, SICKLE CELL; ARGININE; BLOOD TRANSFUSION; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEMOLYSIS; HUMANS; HYPERTENSION, PULMONARY; MALE; RISK FACTORS; TRICUSPID VALVE INSUFFICIENCY;

EID: 84879461266     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12114     Document Type: Article

References (48)

1. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004;11:129-51.
2. Ueda S, Yamagishi S, Okuda S. New pathways to renal damage: role of ADMA in retarding renal disease progression. J Nephrol 2010;23:377-86.
3. Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res 2009;60:461-5.
4. Kakimoto Y, Akazawa S. Isolation and identification of NG3 NG- and NG3 WG-dimethylarginine, W-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-s -hydroxylysine from human urine. J Biol Chem 1970;245:5751-8.
5. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
6. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 2006;26:203-28.
7. Betowski J, Kêdra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006;58:159-78.
8. Tain YL, Huang LT. Asymmetric dimethylarginine: clinical applications in pediatric medicine. J Formos Med Assoc 2011;110:70-7.
9. Millatt LJ, Whitley GS, Li D, Leiper J, Siragy H, Carey R, Johns R. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 2003;108:1493-8.
10. Savale L, Maitre B, Bachir D, Galacteros F, Simonneau G, Parent F. Pulmonary arterial hypertension and sickle cell disease. Presse Med 2013;42:338-46.
11. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95.
12. Lee MT, Small T, Khan MA, Rosenzweig EB, Barst RJ, Brittenham GM. Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. Br J Haematol 2009;146:437-41.
13. Schnog JB, Teerlink T, van der Dijs FPL, Duits AJ, Muskiet FAJ. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol 2005;84:282-6.
14. Kato GJ, Wang Z, Machado RF, Blackwelder WC, Taylor JG, Hazen SL. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol 2009;145:506-13.
15. Landburg PP, Teerlink T, Biemond BJ, Brandjes DP, Muskiet FA, Duits AJ, Schnog JB; CURAMA study group. Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. Blood Cells Mol Dis 2010;44:229-32.
16. Landburg PP, Teerlink T, Muskiet FA, Duits AJ, Schnog JJ; CURAMA study group. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. Am J Hematol 2008;83:577-9.
17. Osanai T, Saitoh M, Sasaki S, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003;42:985-90.
18. Billecke SS, Kitzmiller LA, Northrup JJ, Whitesall SE, Kimoto M, Hinz AV, D'Alecy LG. Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am J Physiol Heart Circ Physiol 2006;291:H1788-96.
19. Davids M, van Hell AJ, Visser M, Nijveldt RJ, van Leeuwen PA, Teerlink T. Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. Am J Physiol Heart Circ Physiol 2012;302:H1762-70.
20. De Gennaro Colonna V, Bianchi M, Pascale V, Ferrario P, Morelli F, Pascale W, Tomasoni L, Turiel M. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit 2009;15:RA91-101.
21. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular. J Nutr 2004;134:2842S-7S.
22. Vladimirova-Kitova LG. Asymmetric dimethylarginine - mechanisms and targets for therapeutic management. Folia Med (Plovdiv) 2008;50:12-21.
23. Pope AJ, Karrupiah K, Xia Y, Cardounel AJ. Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production. J Biol Chem 2009;18:284.
24. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Haematology 2008;1:177-85.
25. Morris CR, Kato GJ. Dysregulated arginine metabolism, hemolysis-associated Pulmonary hypertension and mortality in sickle cell disease. JAMA 2005;294:81-90.
26. Vallance P. The asymmetrical dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in the regulation of nitric oxide generation. Clin Sci 2001;100:159-60.
27. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res 2009;60:448-60.
28. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-7.
29. Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and haemoglobin oxygen desaturation. Haematologica 2009;94:340-7.
30. Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol 2007;24:159-70.
31. Voskaridou E, Tsetsos G, Tsoutsias T, Spyropoulou E, Christoulas D, Terpos E. Pulmonary hypertension in patients with sickle cell/β thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica 2007;92:738-43.
32. Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics 2008;121:777-82.
33. Zuckerman WA, Rosenzweig EB. Pulmonary hypertension in children with sickle cell disease. Expert Rev Respir Med 2011;5:233-43.
34. Ambrusko SJ, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer 2006;47:907-13.
35. Suell MN, Bezold LI, Okcu F, Mahoney DH Jr, Shardonofsky F, Mueller BU. Increased pulmonary artery pressures among adolescents with sickle cell disease. J Pediatr Hematol Oncol 2005;27:654-8.
36. Akinsheye I, Klings ES. Sickle cell anemia and vascular dysfunction: the nitric oxide connection. J Cell Physiol 2010;224:620-5.
37. Qureshi N, Joyce JJ, Qi N. Right ventricular abnormalities in sickle cell anemia: evidence of a progressive increase in pulmonary vascular resistance. J Pediatr 2006;149:23-7.
38. Minniti C, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica 2009;94:340-7.
39. Gordeuk V, Minniti CP, Nouraie M, et al. Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica 2011;96:33-40.
40. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007 Jan;21:37-47.
41. Ataga KI, Sood N, Gent GD, Kelly E, Henderson AG, Jones S, Strayhorn D, Lail A, Lieff S, Orringer EP. Pulmonary hypertension in sickle cell disease. Am J Med 2004;117:665-9.
42. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009;84:618-25.
43. Wilcken DE, Sim AS, Wang J. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol Genet Metab 2007;91:309-17.
44. Yokoro M, Suzuki M, Yatani M, Yamashita H, Takahashi Y, Tsuji H, Kimoto M. Development of an enzyme-linked immunosorbent assay system for the determination of asymmetric dimethylarginine using a specific monoclonal antibody. Biosci Biotechnol Biochem 2012;76:400-3.
45. Tsikas D. Determination of asymmetric dimethylarginine in biological fluids: a paradigm for a successful analytical story. Curr Opin Clin Nutr Metab Care 2008;11:592-600.
46. Pecchini P, Malberti F, Mieth M, Quinn R, Tripepi G, Mallamaci F, Maas R, Zoccali C, Ravani P. Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry. J Nephrol 2012;25:1016-22.
47. El-Beshlawy A, Youssry I, El-Saidi S, El Accaoui R, Mansi Y, Makhlouf A, Taher A. Pulmonary hypertension in β-thalassemia major and the role of L-carnitine therapy. Pediatr Hematol Oncol 2008;25:734-43.
48. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44-53.